Jessica Limberg1, Whitney Kucher1, Genevieve Fasano1, Syed Hoda2, Aya Michaels3, Jennifer L Marti4. 1. Department of Surgery, Weill Cornell Medical College, New York-Presbyterian Hospital, New York, NY, USA. 2. Department of Pathology, Weill Cornell Medical College, New York-Presbyterian Hospital, New York, NY, USA. 3. Department of Radiology, Weill Cornell Medical College, New York-Presbyterian Hospital, New York, NY, USA. 4. Department of Surgery, Weill Cornell Medical College, New York-Presbyterian Hospital, New York, NY, USA. jem9080@med.cornell.edu.
Abstract
BACKGROUND: The optimal management of intraductal papillomas (IPs) without atypia diagnosed on needle core biopsy (NCB) is unclear. This study analyzed the malignancy risk of immediately excised IPs and characterized the behavior of IPs under active surveillance (AS). METHODS: We retrospectively reviewed the pathology and imaging records of patients diagnosed with IPs without atypia on NCB during a 10-year period (1999-2019). The malignancy upgrade rate was assessed in patients who had an immediate surgical excision, and the rates of both radiographic progression and development of malignancy were assessed in a cohort of patients undergoing AS. RESULTS: The inclusion criteria were met in 152 patients with 175 IPs with a mean age of 51 ± 13 years. The average size of the IPs on initial imaging was 8 ± 4 mm. Most of the lesions (57%, n = 99) were immediately excised, whereas 76 (43%) underwent AS with interval imaging with a median follow-up period of 15 months (range, 5-111 months). Among the immediately excised IPs, surgical pathology revealed benign findings in 97% (n = 96) and ductal carcinoma in situ in 3% (n = 3). In the AS cohort, 72% (n = 55) of the IPs remained stable, and 25% (n = 19) resolved or decreased in size. At 2 years, 4% had increased in size on imaging and were subsequently excised, with ductal carcinoma in situ (DCIS, n = 1) and benign pathology (n = 1) noted on final pathology. CONCLUSIONS: In a large series of breast IPs without atypia, no invasive carcinoma was observed after immediate excision, and 96% of the lesions had not progressed on AS. This suggests that patients with IP shown on NCB can safely undergo AS, with surgery reserved for radiographic lesion progression.
BACKGROUND: The optimal management of intraductal papillomas (IPs) without atypia diagnosed on needle core biopsy (NCB) is unclear. This study analyzed the malignancy risk of immediately excised IPs and characterized the behavior of IPs under active surveillance (AS). METHODS: We retrospectively reviewed the pathology and imaging records of patients diagnosed with IPs without atypia on NCB during a 10-year period (1999-2019). The malignancy upgrade rate was assessed in patients who had an immediate surgical excision, and the rates of both radiographic progression and development of malignancy were assessed in a cohort of patients undergoing AS. RESULTS: The inclusion criteria were met in 152 patients with 175 IPs with a mean age of 51 ± 13 years. The average size of the IPs on initial imaging was 8 ± 4 mm. Most of the lesions (57%, n = 99) were immediately excised, whereas 76 (43%) underwent AS with interval imaging with a median follow-up period of 15 months (range, 5-111 months). Among the immediately excised IPs, surgical pathology revealed benign findings in 97% (n = 96) and ductal carcinoma in situ in 3% (n = 3). In the AS cohort, 72% (n = 55) of the IPs remained stable, and 25% (n = 19) resolved or decreased in size. At 2 years, 4% had increased in size on imaging and were subsequently excised, with ductal carcinoma in situ (DCIS, n = 1) and benign pathology (n = 1) noted on final pathology. CONCLUSIONS: In a large series of breast IPs without atypia, no invasive carcinoma was observed after immediate excision, and 96% of the lesions had not progressed on AS. This suggests that patients with IP shown on NCB can safely undergo AS, with surgery reserved for radiographic lesion progression.
Authors: Laura Liberman; Carmen Tornos; Renata Huzjan; Lia Bartella; Elizabeth A Morris; D David Dershaw Journal: AJR Am J Roentgenol Date: 2006-05 Impact factor: 3.959
Authors: Amy E Cyr; Deborah Novack; Kathryn Trinkaus; Julie A Margenthaler; William E Gillanders; Timothy J Eberlein; Jon Ritter; Rebecca L Aft Journal: Ann Surg Oncol Date: 2010-11-03 Impact factor: 5.344
Authors: Monica Rizzo; Jared Linebarger; Michael C Lowe; Lin Pan; Sheryl G A Gabram; Leonel Vasquez; Michael A Cohen; Marina Mosunjac Journal: J Am Coll Surg Date: 2012-01-11 Impact factor: 6.113
Authors: Leah S Gendler; Sheldon M Feldman; Ronald Balassanian; Mary A Riker; Stanley K Frencher; Denise B Whelan; Shalini Anne; Joshua D Gross; Jean-Marc Cohen; Susan K Boolbol Journal: Am J Surg Date: 2004-10 Impact factor: 2.565
Authors: Song-Hee Han; Milim Kim; Yul Ri Chung; Bo La Yun; Mijung Jang; Sun Mi Kim; Eunyoung Kang; Eun-Kyu Kim; So Yeon Park Journal: J Breast Cancer Date: 2018-03-23 Impact factor: 3.588
Authors: Xiaoxian Li; Michael Aho; Mary S Newell; Kelly Clifford; Jay G Patel; Stephanie Jou; Michael A Cohen Journal: Clin Imaging Date: 2019-12-03 Impact factor: 2.420